Biomarker for CRC Screening
Colorectal cancer (CRC) is the second most common cause for cancer-related death worldwide. Lifetime risk of CRC is approximately 6% and of colorectal adenoma approximately 50%. Early detection and removal of adenoma has been shown to reduce the incidence and mortality of CRC. Colonoscopy remains to be the gold standard for detecting CRC and pre-malignant adenomas. However, this procedure is costly, labor intensive and uncomfortable. We have developed a new screening tool based on detecting tumor derived molecular changes in stool. This test provides a non-invasive means for detecting CRC.
10/MED/349
Inventor(s): Professor Joseph SUNG, Department of Medicine and Therapeutics
Patent Status: US Patent Pending Licensing Status: Available for licensing
香港
